Skip to content

Polaris Oncology Survivor Transition (POST) System

Polaris Oncology Survivor Transition (POST) System

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02637349
Acronym
POST
Enrollment
200
Registered
2015-12-22
Start date
2016-11-30
Completion date
2019-08-31
Last updated
2019-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The POST's public health impact is likely to be substantial because it will improve cancer survivorship planning, which is currently an important deficiency in cancer care recognized by the Institute of Medicine and the American College of Surgeons. The POST may have many potential benefits for patients such as: 1. improved long-term health outcomes; 2. improved psychosocial outcomes and quality of life; 3. smoother transitions back into old and new life roles; and 4. improved continuity and coordination of care between providers. Most importantly, the POST's influence may reach beyond the patients it directly serves as it could help scientists and health care providers understand the potential benefits of cancer survivorship planning and how to best design and implement survivorship planning when patients are ending treatment for cancer.

Detailed description

By January 2015, oncology care providers will be expected to craft Survivorship Care Plans (SCPs) for all individuals ending active treatment for cancer; however, there is a lack of systematic study of the impact survivorship planning has on patients, providers, or healthcare systems. The Polaris Oncology Survivorship Transition (POST) program is a web-based system that incorporates recommendations from the Institute of Medicine (IOM) and American College of Surgeons (ACS) to assist with cancer survivorship planning. It is a patient-centered approach that integrates input from both the treating oncology team and the patient. Phase 1 built and iteratively modified (N=25) the POST system and Phase 2 will test whether the SCPs impact patient and provider outcomes using a single blind, randomized controlled trial (RCT). Breast cancer patients (n=230) transitioning out of active treatment will be recruited and randomly assigned to receive Treatment as Usual (n=115) or the POST (n=115). All participants will be assessed at 1, 3, and 6 months by a research assistant blind to baseline status and group assignment. Primary outcomes will include quality of life, mechanisms of action such as confidence in entering survivorship, and other outcomes such as (1) depression and anxiety, (2) adherence to medical and behavioral health recommendations, (3) health care utilization, and (4) patient and provider satisfaction with the POST system.The POST will innovate the clinical setting through being the first system to produce computer generated tailored survivorship plans fully reflecting IOM recommendations and the new ACS 2015 requirements; incorporating information from both the oncology provider and the patient; featuring readily available plug in for two-way electronic health record integration; providing dynamic, electronic referrals for specialized support services; and facilitating care coordination between the oncologist and PCP. This study's impact will be significant. If hypotheses are confirmed, clear scientific evidence will exist for supporting survivorship care planning into oncology clinical practice. If hypotheses are disconfirmed, important lessons will guide future directions for care planning, including whether failure to affect outcomes was due to failure to impact several hypothesized mechanisms of action.

Interventions

BEHAVIORALPOST Intervention

POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.

BEHAVIORALPOST Treatment as Usual

The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.

Sponsors

University of Massachusetts, Worcester
CollaboratorOTHER
Polaris Health Directions
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years or older * Confirmed diagnosis of breast cancer (not metastatic) * A final active treatment appointment scheduled with oncology team * Able to read or understand English at a 6th grade level

Exclusion criteria

* Altered mental status (e.g., psychosis, delirium, disorientation) * Visual problems preventing them from reading the assessment and reports * Severe illness that would preclude conversation or interface with a computer (e.g.,persistent nausea/vomiting, severe pain) * Unable to read or understand English at a 6th grade level * Characteristics that would prevent adequate follow-up (e.g., lack of a telephone)

Design outcomes

Primary

MeasureTime frameDescription
Changes in Quality of Life1,3, 6 months after entering the studyQuality of life will be measured at baseline and at the follow-ups using the City of Hope Quality of Life measure. Improvement in quality of life is the primary goal of survivorship planning.

Secondary

MeasureTime frameDescription
Changes in Depression1,3,6 months after entering studyChanges in depression will be measured by the Patient Health Questionnaire -9 (PHQ-9).
Changes in Anxiety1,3,6 months after entering studyChanges in anxiety will be measured by the General Anxiety Disorder 7-item measure (GAD-7).
Change in Health care utilization6-months after entering the studyParticipants' medical charts will be reviewed six months after termination of active treatment for frequency and appropriateness of oncology, primary care, and emergency room visits, as well as hospitalizations.
Changes in Confidence in Transitioning to Survivorship1,3,6 months after entering the studyNational Cancer Institute (NCI) and the Institute of Medicine (IOM) have emphasized that SCPs should help improve patients' feelings of preparedness and confidence in managing and understanding the next steps at the end of treatment. This will be measured at baseline and follow-up sessions using the Confidence in Survivorship Information Questionnaire (CSI).
Change in Patient Satisfaction with the POST system1,3,6 months after entering the studyPatients will be asked to assess their satisfaction with the POST system.
Change in Provider Satisfaction with the POST system1,3,6 months after entering the studyProviders will be asked to assess their satisfaction with the POST system.
Change in Patient Satisfaction and Usefulness of SCP1,3,6 months after entering the studyPatients will be asked to assess their satisfaction with the POST program and with the content and quality of the SCP.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026